Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells

Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells

Bibliographic Details
Main Authors:	Monique Matsuda, Rafael André da Silva, Vinicius Moraes de Paiva Roda, Mônica Valéria Marquezini, Mário Luiz Ribeiro Monteiro, Dânia Emi Hamassaki
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10971667/?tool=EBI

Similar Items

Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions
by: Weiyong Shen, et al.
Published: (2017-03-01)

Müller Cells Stabilize Microvasculature through Hypoxic Preconditioning
by: Kepeng Ou, et al.
Published: (2019-03-01)

Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells
by: Amirfarbod Yazdanyar, et al.
Published: (2023-06-01)

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

VEGF Mediates Retinal Müller Cell Viability and Neuroprotection through BDNF in Diabetes
by: Yun-Zheng Le, et al.
Published: (2021-05-01)

Importance of Müller Cells
by: Sabiha Gungor Kobat, et al.
Published: (2020-08-01)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
by: Junyeop Lee, et al.
Published: (2022-03-01)

Bevacizumab effect on viability of free groin flaps in rats
by: João Mamede, et al.
Published: (2023-07-01)

Effects of paclitaxel on Müller cells in retina
by: Yi-Xuan Xi, et al.
Published: (2023-11-01)

A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept and laser for retinopathy of prematurity
by: Chang, ET, et al.
Published: (2022)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
by: Tuncay Topal, et al.
Published: (2017-06-01)

Oxygen and Drug-Carrying Periodic Mesoporous Organosilicas for Enhanced Cell Viability under Normoxic and Hypoxic Conditions
by: Ravi Kumar, et al.
Published: (2022-04-01)

TheEffect of bevacizumab and hydroalcohlic Extract of Matricaria chamomilla on cell viability and nitric oxide production of the colorectal cancer cell line (HT-29)
by: N Danaei, et al.
Published: (2016-03-01)

Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab
by: Xuan Cao, et al.
Published: (2023-01-01)

Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study
by: Tereza Kanadani, et al.
Published: (2024-02-01)

Inhibition of epigenetic and cell cycle-related targets in glioblastoma cell lines reveals that onametostat reduces proliferation and viability in both normoxic and hypoxic conditions
by: Darja Lavogina, et al.
Published: (2024-02-01)

Functions of retinal astrocytes and Müller cells in mammalian myopia
by: Xuhong Zhang, et al.
Published: (2022-11-01)

Müller cell degeneration and microglial dysfunction in the Alzheimer’s retina
by: Qinyuan Alis Xu, et al.
Published: (2022-10-01)

Contribution of Müller Cells in the Diabetic Retinopathy Development: Focus on Oxidative Stress and Inflammation
by: Raul Carpi-Santos, et al.
Published: (2022-03-01)

Electrical Stimulation Induces Retinal Müller Cell Proliferation and Their Progenitor Cell Potential
by: Sam Enayati, et al.
Published: (2020-03-01)

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration
by: Simon D Archambault, et al.
Published: (2024-01-01)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
by: Jing Chen, et al.
Published: (2023-10-01)

Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study
by: M. Yu. Fedyanin, et al.
Published: (2022-03-01)

Aflibercept and Ranibizumab Modulate Retinal Pigment Epithelial Cells Function by Acting on Their Cross Talk with Vascular Endothelial Cells
by: Stefano De Cillà, et al.
Published: (2020-02-01)

Effects of Adult Müller Cells and Their Conditioned Media on the Survival of Stem Cell-Derived Retinal Ganglion Cells
by: Xandra Pereiro, et al.
Published: (2020-07-01)

Harnessing Astrocytes and Müller Glial Cells in the Retina for Survival and Regeneration of Retinal Ganglion Cells
by: Hyung-Suk Yoo, et al.
Published: (2021-05-01)

IL-33 regulates Müller cell-mediated retinal inflammation and neurodegeneration in diabetic retinopathy
by: Josy Augustine, et al.
Published: (2023-09-01)

Dengue Virus Infection of Human Retinal Müller Glial Cells
by: Genevieve F. Oliver, et al.
Published: (2023-06-01)

Genetic and epigenetic regulators of retinal Müller glial cell reprogramming
by: Xueqi Xiao, et al.
Published: (2023-08-01)

Restoring vision and rebuilding the retina by Müller glial cell reprogramming
by: Devansh Agarwal, et al.
Published: (2023-02-01)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
by: Kumar, K, et al.
Published: (2013)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
by: Kumar, K, et al.
Published: (2013)

Proteasome Inhibitors Decrease the Viability of Pulmonary Arterial Smooth Muscle Cells by Restoring Mitofusin-2 Expression under Hypoxic Conditions
by: I-Chen Chen, et al.
Published: (2022-04-01)

Preliminary Study of Different Treatment Responses between Bevacizumab, Aflibercept and Dexamethasone Implant According to Renal Function in Diabetic Macular Edema Patients
by: Tae Hwan Moon, et al.
Published: (2022-11-01)

Vitreous protein networks around ANG2 and VEGF in proliferative diabetic retinopathy and the differential effects of aflibercept versus bevacizumab pre-treatment
by: Ingeborg Klaassen, et al.
Published: (2022-12-01)

The effect of intravitreal bevacizumab injection on the corneal endothelial cells
by: Akbar Derakhshan, et al.
Published: (2016-04-01)

The Effect of Intravitreal Bevacizumab on Apoptosis of Rat Retina Cells
by: Özcan Kayıkçıoğlu, et al.
Published: (2013-01-01)

Correction: Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells
Published: (2012-01-01)

Retinal Injury Activates Complement Expression in Müller Cells Leading to Neuroinflammation and Photoreceptor Cell Death
by: Steven J. Tabor, et al.
Published: (2023-06-01)